Product-led growth for startups under 20 people for healthcare and life sciences in the Middle East

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the Middle East. In this market, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing, so the way you install product-led growth has to be shaped to that reality from day one.

The under-20-person version of product-led growth is not a diluted enterprise playbook. It is using product usage — not a rep — as the primary lead source with different constraints: no headcount, no politics, and no time to be wrong for long.

Own it personally as a founder or lean-in operator for the first quarter. Hiring a specialist too early replaces context with process.

Pick one channel, one trigger, one message. Two of anything at this stage is too many and none of them will work.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the Middle East it is compounded by the fact that senior-relationship access, not product is what actually gates growth. Product-led growth is only useful here when it is pointed at both constraints at once.

Instrument self-serve activation to paid conversion in a spreadsheet if you have to. Legibility beats sophistication under 20 people.

The startup-specific trap is bolting PLG onto a product that requires a demo to understand, usually because a well-meaning advisor points at what worked at their $50m company. Ignore.

Budget rules: whatever you spend on tools, spend the same on the person operating them. Under-tooling is fine; under-humaning is not.

A working product-led growth function at 15 people is a genuine moat — most competitors of that size do not have one, and the discipline carries forward as the company grows.

Concretely for healthcare and life sciences in the Middle East: the healthcare teams that install this get past procurement instead of dying in it, and one sovereign or family-office win in the Middle East justifies a full year of program spend. That is the reason it is worth installing product-led growth deliberately for this market rather than importing a playbook designed for somewhere else.